USPTO serial 97978060
CLARIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 25, 2024
- Examiner
- KETCHUM, BRENDAN J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CLARIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Philadelphia, PA, US
Philadelphia, PA, US
Philadelphia, PA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David M. Kramer
David M. Kramer Buchanan Ingersoll & Rooney, P.C.1700 K Street N.W.Suite 300Washington, DC 20006Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer software for use in collecting, managing and analyzing quality of life, subjective symptom, and similar self-observation data self-reported by patients in pharmaceutical clinical trials; downloadable computer software for the collection, interpretation, evaluation, auditing, management, processing, tracking and viewing of data in the field of clinical trials; downloadable computer software for calibrating and managing medical instruments used in clinical trials; none of the aforesaid goods relating to the custom design and development of computer hardware and software except as relating to medical research or medical clinical trials; none of the foregoing for in vitro diagnostics, detection of contaminants, infectious disease surveillance, disease prevention and control, and/or antimicrobial stewardship | ACTIVE | — |
| 010 | Medical devices for the respiratory system, namely, for measuring, monitoring, collecting, recording, transmitting, and evaluating data regarding expiratory flow, respiratory symptoms, and respiratory medication consumption; medical devices for measuring, monitoring, collecting, recording, transmitting, and evaluating data concerning expiratory flow and cardiopulmonary behavior; portable medical devices with sensors to monitor the physical movements of a patient wearing or carrying the device; medical apparatus and equipment for examining lung function and parts therefor; medical electronic apparatus and equipment, namely, spirometers, pulse oximeters, and electrocardiographs; integrated medical research systems comprising wearable devices with sensors, namely, accelerometers, gyroscopes, and magnetometers, to monitor the physical movements of an individual wearing the device and downloadable computer software and monitors used during the process of monitoring the movement of an individual; none of the foregoing for in vitro diagnostics, detection of contaminants, infectious disease surveillance, disease prevention and control, and/or antimicrobial stewardship | ACTIVE | — |
| 035 | Computerized database management services in connection with clinical trials of medical and clinical diagnostic products; business consulting services in relation to clinical data and regulatory management for healthcare industry organizations, namely, biopharmaceutical organizations, contract research organizations, medical device companies, and hospitals; database management services, namely, aggregating and organizing data in connection with clinical trials of medical and clinical diagnostic products; none of the foregoing for in vitro diagnostics, detection of contaminants, infectious disease surveillance, disease prevention and control, and/or antimicrobial stewardship | ACTIVE | — |
| 041 | Business training services, namely, scientific and regulatory leadership development training for healthcare industry organizations, namely, biopharmaceutical organizations, contract research organizations, medical device companies, and hospitals; training and development in the field of conducting clinical trials, namely, conducting seminars and workshops in the field of clinical trials; training in the field of computer software support, namely, conducting seminars and workshops in the field of software support; none of the foregoing for in vitro diagnostics, detection of contaminants, infectious disease surveillance, disease prevention and control, and/or antimicrobial stewardship | ACTIVE | — |
| 042 | Data automation and collection service using proprietary software to evaluate, analyze, and collect data; consulting services in the field of clinical trials of medical and clinical diagnostic products; design and development of computer software for collecting, storing, managing, analyzing, and reporting on healthcare data and clinical trial data; providing temporary use of non-downloadable computer software for collecting, storing, managing, analyzing, and reporting on healthcare data and clinical trial data; design and development of computer software for data analytics, data visualization, and data workflow in the healthcare and pharmaceutical industries; providing temporary use of non-downloadable computer software for data analytics, data visualization, and data workflow in the healthcare and pharmaceutical industries; providing temporary use of non-downloadable software for use in screening and monitoring patients for suicide risk; providing temporary use of non-downloadable software for measuring expiratory flow volume and monitoring, collecting, and evaluating expiratory flow data; laboratory services, namely, imaging core lab services; technical consulting services in the field of clinical trials; providing an on-line computer database in the field of clinical trials; none of the aforesaid services relating to the custom design and development of computer hardware and software except as relating to medical research or medical clinical trials; none of the foregoing for in vitro diagnostics, detection of contaminants, infectious disease surveillance, disease prevention and control, and/or antimicrobial stewardship | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by eResearchTechnology, Inc.
- Other trademarks owned by eResearchTechnology, Inc.
- Other trademarks owned by eResearchTechnology, Inc.
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named CLARIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 29, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jan 22, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 25, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 25, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 23, 2024 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| May 23, 2024 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Apr 22, 2024 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Apr 22, 2024 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Apr 17, 2024 | IROA | RESPONSE TO ITU OFFICE ACTION ENTERED | — |
| Apr 17, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 16, 2024 | INCD | ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST | — |
| Apr 8, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 20, 2024 | IUAF | USE AMENDMENT FILED | — |
| Mar 20, 2024 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Mar 20, 2024 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Mar 20, 2024 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Nov 22, 2023 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Nov 22, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 22, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 22, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 22, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 22, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 7, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 25, 2023 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Sep 25, 2023 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Sep 25, 2023 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Jun 26, 2023 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| May 23, 2023 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| May 22, 2023 | APET | ASSIGNED TO PETITION STAFF | — |
| May 4, 2023 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jan 20, 2023 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 3, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 3, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 14, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 29, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 29, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 29, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 29, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 29, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 25, 2022 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 25, 2022 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Oct 13, 2022 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Oct 7, 2022 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Oct 3, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 23, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 22, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 22, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 22, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 22, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 22, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 12, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 18, 2022 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Mar 18, 2022 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Nov 15, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 6, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 6, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 6, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 6, 2021 | NWAP | NEW APPLICATION ENTERED | — |